Affiliations: National Public Health Institute, Department of Epidemiology and Health Promotion, Helsinki, Finland | Rigshospitalet, Department of Medicine B, Copenhagen, Denmark | Rigshospitalet, Department of Clinical Pharmacology Q, Copenhagen, Denmark
Note: [] Address for correspondence: Johan Eriksson, MD, PhD, National Public Health Institute, Department of Epidemiology and Health Promotion, Mannerheimintie 166, 00300 Helsinki, Finland. E‐mail: Johan.Eriksson@ ktl.fi.
Abstract: A possible relationship between the pathogenesis of type 2 diabetes and coenzyme Q_{10} (CoQ_{10}) deficiency has been proposed. The aim of this study was to assess the effect of CoQ_{10} on metabolic control in 23 type 2 diabetic patients in a randomized, placebo‐controlled trial. Treatment with CoQ_{10} 100 mg bid caused a more than 3‐fold rise in serum CoQ_{10} concentration (p<{}0.001). No correlation was observed between serum CoQ_{10} concentration and metabolic control. No significant changes in metabolic parameters were observed during CoQ_{10} supplementation. The treatment was well tolerated and did not interfere with glycemic control, therefore CoQ_{10} may be used as adjunctive therapy in patients with associated cardiovascular diseases.
Journal: Biofactors, vol. 9, no. 2-4, pp. 315-318, 1999
